findmyKOL

Edward Lain, MD

Enriched profile

Board-Certified Dermatologist and Chief Medical Officer · Sanova Dermatology

ORCIDNPI
Region🇺🇸 Austin, TX · South Central · United StatesSpecialtyDermatologyFocusAcne and Rosacea Treatments and Effects+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Edward Lain is Board-Certified Dermatologist and Chief Medical Officer at Sanova Dermatology. OpenAlex indexes 145 publications with 1,284 citations (h-index 19); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Edward "Ted" Lain, MD, is Board-Certified Dermatologist and Chief Medical Officer at Sanova Dermatology. The public record shows 145 publications with 1,284 citations (h-index 19), centered on Acne and Rosacea Treatments and Effects, Dermatology and Skin Diseases, Dermatologic Treatments and Research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 47 companies.

  • Most recent indexed publication: 2024 · Dermatology and therapy
  • Top research focus: Acne and Rosacea Treatments and Effects
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 47 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Acne / Hidradenitis3 trialsAcne Vulgaris3 trialsPsoriasis / Psoriatic Arthritis2 trialsPsoriasis (Derm)1 trialAtopic Dermatitis / Eczema1 trialKeratosis, Actinic1 trialKeratosis1 trialCarcinoma, Squamous Cell1 trialCarcinoma in Situ1 trialBowen's Disease1 trialBasal Cell Carcinoma1 trialCutis Laxa1 trialIchthyosis1 trialObesity1 trialOverweight1 trialVitiligo1 trial

Research focus

OpenAlex concept fingerprint
Acne and Rosacea Treatments and EffectsDermatology and Skin DiseasesDermatologic Treatments and ResearchSkin Protection and AgingPsoriasis: Treatment and Pathogenesis

Drugs & molecules

across trials, industry payments and publications
Akliefgeneric · TrifaroteneClinical trialsIndustry payments108Publications1Siliqgeneric · BrodalumabClinical trialsIndustry payments91Publications2Klisyrigeneric · TirbanibulinClinical trialsIndustry payments78Publications2

Works with

trial sponsors and companies reporting payments
Eli Lilly and CompanyClinical trials1Industry payments10Galderma Laboratories, L.P.Clinical trialsIndustry payments251UCB, Inc.Clinical trialsIndustry payments212

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
145publications

Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.

1,284citations

Total citations across indexed works.

19h-index

Hirsch index (OpenAlex). i10-index 36.

Clinical & industry

trials, payments and federal funding
13clinical trials

Investigator role on registered studies.

View trials
47companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Industry payments

Updated 27 Aug 2026

47 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    90.2%
    Porphyrin Precursor88.9%
    Aminolevulinic acid hcl100%
    Part B, office-administered19 patients
    Calcineurin inhibitor0.8%
    Tacrolimus100%
    Part D28 patients
  • Anti-infectives

    3.8%
    Azole Antifungal2.4%
    Ketoconazole92%Fluconazole8%
    Part D<11 patients
    Tetracycline-class Drug0.9%
    Doxycycline Hyclate62%Minocycline Hcl38%
    Part D<11 patients
  • Dermatology

    2.5%
    Corticosteroid1.5%
    Triamcinolone Acetonide55%Triamcinolone acetonide45%
    Part D + Part B41 patients
    Interleukin-4 Receptor alpha Antagonist0.4%
    Dupixent Pen100%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/edward-lain-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • Instagram

    instagram.com/drtedlain

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • LinkedIn

    linkedin.com/in/drtedlain

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
  • Instagram

    Instagram: @drtedlain (Dr. Ted Lain MD & MBA, FAAD)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • X / Twitter

    X (Twitter): @DrLain

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Baylor College of Medicine

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sanovadermatology.com
  • MBA

    Rice University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sanovadermatology.com
  • Dermatology residency

    University of Arkansas for Medical Sciences

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atxresearch.com
  • Internal Medicine internship

    University of Arkansas for Medical Sciences

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atxresearch.com
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dermatologytimes.com

Editorial & leadership roles

journal and society appointments
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermsquared.com
  • Featured guest

    JCAD (Journal of Clinical and Aesthetic Dermatology) podcast: "Long-Term Results of Deuruxolitinib for Alopecia Areata"

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jcadonline.com
  • Featured guest

    Dermatology Times video segment "Personal Care Products With Ted Lain, MD, MBA"

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologytimes.com
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.